Printer Friendly

Research and Markets: Analysis of Top Oncology Drug Candidates in Phase III of Clinical Evaluation.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12053) has announced the addition of Large Pharma: 2004 A Year Of Progress to their offering.

The gross majority of all drugs, which reach late stage of development, are someway or another passed on to the large pharmaceutical companies because they hold the capital needed to conduct the expensive clinical trials as well as the regulatory commitment needed to gain an approval. In this report we analyse the progress made by the large pharmaceutical companies top oncology drug candidates whom have reached Phase III clinical evaluation. This report provides you with update information on the most recent advances made and the competitive struggle that exists between the large pharmaceutical companies.

Hallmarks of 2004 includes that BAY 43-9006 and CCI-779 were granted Fast Track Designition for treating patients with renal cell carcinoma. Fast Track Designition were also awarded to Xcytrin for treating patients brain metastases. In turn, Orphan Drug Status was granted to BAY 43-9006 for renal cancer, PI-88 for melanoma and Revlimid for myelodysplastic syndromes. Four FDA approvals were also reported during 2004. Avastin as well as Erbitux were both approved as treatment for colorectal cancer whereas Alimta was approved as treatment for mesothelioma. And very recently, Tarceva was approved as monotherapy to treat non-small cell lung cancer.

This report covers the following stories:

--Approval and New Development of Erbitux

--Two Drugs at War; Iressa versus Tarceva

--Breast Cancer Competition

--European Approval for Estrogen Receptor Downregulator

--Dual Kinase Inhibitor with Improved Effect in Breast Cancer

--Side effects & resistance

--Epothilone B analogues in Patients with Breast/Prostate Cancer

--Avastin safety warning unlikely limit use

--FDA backs drug for lung cancer treatment

--Late Stage Cancer Vaccine Back To The Bench

--Discontinued Phase III Studies: NSCLC

--New Therapeutic Option for Patients with Renal Cell Carcinoma

--Fast Track Status in Advanced Renal Cell Carcinoma

--Option For The Treatment of Colorectal Cancer

--New Drug to Replace Standard Chemotherapy in Colon Cancer?

--A Drug More Potent than Camptothecin

--Additional Revenues for Gleevec

--Overcoming Gleevec resistance

--Reactivating DNA-damaging in hypoxic tumors

--New agent with antimyeloma activity

For more information visit http://www.researchandmarkets.com/reports/c12053
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 20, 2005
Words:359
Previous Article:CONNECTIONS To Address Issues Fundamental to the Digital Home.
Next Article:O'Reilly Automotive Standardizes on Vocollect Voice-Directed Work Solution.


Related Articles
Titan Reports First Quarter 2000 Financial Results.
Lorus Therapeutics Presents Virulizin Results At International Chemotherapy Symposium.
OSI Pharmaceuticals Reports 2001 Financial Results.
Miravant Announces Fourth Quarter and 2001 Results.
OSI Pharmaceuticals Announces Fiscal 2002 Financial Results.
OSI Pharmaceuticals Announces Fiscal 2003 Financial Results; Conference Call and Webcast to Follow.
PHASE IIB MBI 594AN STUDY VALIDATES ANTI-ACNE PROPERTIES.
LORUS SIGNS VIRULIZIN SUPPLY PACT WITH BIOVECTRA.
Idera Pharmaceuticals Announces Formation of Oncology Clinical Advisory Board; Accomplished Physicians and Scientists in Cancer Drug Development.
In-Depth Competitive Landscape Assessment of the Cancer Immunotherapy Market Place.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters